People in the News

Dec 12, 2018

Melissa Lueke, Eric Rasmussen, Bryan Baldasare

Executive Vice President and Chief Financial Officer at Meridian Bioscience, Melissa Lueke, will retire from her position effective January 1, 2019. Lueke, who has been at Meridian for 20 years, will remain with the firm in a paid financial consulting role with a renewable contract of three years.

Meridian also promoted Eric Rasmussen from his role as EVP of Corporate Development to the position of EVP, CFO, and Principal Financial Officer, also effective January 1, 2019. Rasmussen was hired by Meridian in June of 2018, and previously served in corporate development and financial leadership roles at Lear Corporation, an automotive seating and electrical systems supplier. Rasmussen has also served on the advisory board of Exploragen, a DNA lifestyle company.

Meridian has also promoted Bryan Baldasare to the role of Chief Accounting Office. Baldasare has been with Meridian since 2000, and most recently served as Senior Vice President, Corporate Controller and Treasurer.

Dec 11, 2018

Catherine Friedman, Alex Aravanis

Grail has appointed Catherine Friedman as chair of the firm's board of directors. Friedman succeeds Bill Rastetter, who will continue to serve as a director of the firm's board. Friedman joined the board in July 2017. She previously held numerous executive positions during an investment banking career with Morgan Stanley, including managing director head of West Coast Healthcare, and co-head of the biotechnology practice. Friedman is also a board member at Altaba, Radius Health, and Lyell Immunopharma.

Grail has also appointed Alex Aravanis as Chief Scientific Officer and head of research and development. Aravanis is a cofounder of Grail. Prior to being CSO, Aravanis served as VP of research and development. He previously served as senior director of research and development for Illumina. In addition, Aravanis served as VP of development and CSO of Sapphire Energy and was a cofounder and VP of engineering of Pria Diagnostics.

Dec 11, 2018

Hans Clevers

The board of directors of Roche Holding has proposed Hans Clevers as a new board member. He is scheduled to be elected to the board at the company's annual general meeting on March 5, 2019. Clevers is a professor of molecular genetics at the University Medical Center Utrecht in the Netherlands.

Dec 10, 2018

Cynthia Collins

Cynthia Collins has joined the board of directors of Editas Medicine. Most recently, she was the CEO of Human Longevity. Prior to that, she was CEO/GM of General Electric's Healthcare Cell Therapy Business, Lab Businesses, and Clarient Diagnostics. Before that, she was president and CEO of GenVec, and prior to that, group vice president of the Cellular Analysis Business of Beckman Coulter. Collins holds a BS degree in microbiology from the University of Illinois, Urbana, and an MBA from the University of Chicago Booth School of Business.

Dec 10, 2018

Daniel O'Day, William Anderson

Daniel O'Day will leave his post as CEO and corporate executive committee member of Roche Pharmaceuticals at the end of December to become CEO and board chairman of Gilead Sciences, effective March 1, 2019.

In the interim period, he will provide support to Roche to ensure a smooth transition to his successor, William Anderson, who will become CEO of Roche Pharmaceuticals effective January 1, 2019. Anderson is currently CEO of Roche-owned Genentech, which he joined in 2006. In previous roles, he led Genentech's immunology business unit, headed oncology sales and marketing, and led global product strategy. Anderson holds a master of science degree in management and chemical engineering from MIT.

Dec 10, 2018

Prahlad Singh

Prahlad Singh has been appointed president and COO of PerkinElmer, effective Jan. 1, 2019. Singh will be responsible for the Discovery and Analytical Solutions and the Diagnostics operating divisions. PerkinElmer said the change is being made to "better facilitate synergies across the businessess to identify incremental growth opportunities, create operating efficiencies, and most importantly, accelerate the pace of innovation across the company." He joined PerkinElmer in 2014 as president of the diagnostics business and was elected an officer in 2016 and executive vice president in 2016. Prior to joining the firm, Singh was GM of GE Healthcare's women's health business, and before that he held senior executive level positions in strategy, business development, and M&A at GE and at Philips Healthcare. 

Dec 10, 2018

Bradley Cole

Castle Biosciences announced Bradley Cole has been appointed to its board. Cole is the CFO of Genomic Health and has more than 30 years of experience in finance and operations in the diagnostics and life sciences industries. He also has served as COO of Genomic Health. Prior to joining the firm, he was VP of finance and business development for the endovascular solutions group at Guiidant, and was VP and GM of vascular surgery business unit of Guidant. 

Dec 07, 2018

E. Robert Wassman

NeuroPointDx, a division of Stemina Biomarker Discovery, has appointed E. Robert Wassman as its medical director. Wassman has acted as chief medical officer (CMO) for several companies in the genetic testing, biomarker discovery, and diagnostic development space. He previously served as CMO of Lineagen from 2015 to 2017. Before that, he served as CMO at Rosetta Genomics from 2012 to 2015. Wassman has also previously served as CMO at other companies in the personalized medicine space over the past 35 years, including Genzyme Genetics, Celula, Ambry Genetics, and Alfigen. 

Dec 07, 2018

Caroline Loew, Stanley Lapidus, Robert Langer

Glympse Bio has appointed Caroline Loew as the firm's president and CEO. Loew previously served as VP, heading of R&D strategy and planning at Bristol-Myers Squibb. In addition, she has served in senior roles at Merck and phRMA over the past 20 years, where she led teams in drug development, regulatory policy, market access, and commercial. 

Glympse has also appointed Stanley Lapidus as the firm's chairman and Robert Langer to the firm's board of directors. Lapidus has been the founding CEO of four medical technology companies, including Cytyc, Exact Sciences, Helicos, and SynapDx.

Dec 06, 2018

Hilde Furberg, Guido Oelkers

Blueprint Genetics has appointed Hilde Furberg as chairman of its board of directors. Furberg previously served as head of rare disease Europe at Sanofi Genzyme. She is also currently an industrial advisor to Investinor and a board member of BerGenBio, Calliditas, and Tappin. Hilde has previously worked at companies including Baxter and Genzyme, and has also been a board member of Probi, Pronova, Clavis, and Algeta.

In addition, Blueprint has appointed Guido Oelkers as a senior advisor to the firm. Oelkers currently serves as CEO of Swedish Orphan Biovitirum. Previously, he served in roles including CEO of BSN Medical, CEO of Gambro, CEO of Invida, and a number of executive commercial operations roles in companies such as Nycomed, DKSH Group, and Aventis. 

Dec 06, 2018

Bradley Cole

Castle Biosciences has appointed Bradley Cole to its board of directors. Cole currently serves as Genomic Health's CFO. In addition, Cole served as both chief operating officer and CFO at the firm. Previously, Cole served as VP of finance and business development for the Endovascular Solutions Group at Guidant. Prior to that, he served as VP and general manager of the vascular surgery business unit of Guidant. Previously, he served as CFO at Endovascular Technologies until it was acquired by Guidant in 1997. Before Endovascular, he served as CFO at Applied Biosystems until 1994. 

Nov 30, 2018

Stevan Knezevich

DermTech has appointed Stevan Knezevich to its scientific advisory board. Knezevich has a PhD in pathology and laboratory medicine from the University of Vancouver, B.C., and a MD from the University of Toronto. 

Nov 28, 2018

Joseph Khoury

Angle has appointed Joseph Khoury to its scientific advisory board. Khoury currently serves as a tenured professor of pathology and laboratory medicine at the University of Texas MD Anderson Cancer Center.

Nov 28, 2018

Benjamin Reed, James Fullerton-Batten, Nick Ash, Matt Pomroy

Epistem has completed its board appointments: Benjamin Reed will join as commercial director — he had previously served as Epistem's pharmacogenomics business development director; James Fullerton-Batten joins the board from Concept Life Sciences, where he served as finance director; Nick Ash joins the board from Source BioScience, where he served as CEO; and Matt Pomroy joins the board as a non-executive investor representative from Foresight Group.


Nov 26, 2018

Reginald Seeto

CareDx has appointed Reginald Seeto to the newly created role of president and chief business officer. Seeto has 20 years of experience in commercial operations, corporate development, and strategy, most recently serving as chief operating officer at Ardelyx. He has also worked at AstraZeneca/Medimmune and was a member of the MedImmune executive team. His responsibilities there included leading corporate development and strategy, global strategic marketing, and portfolio management for all therapeutic areas, as well as a country leadership role at AstraZeneca in Thailand. Before AstraZeneca, Seeto held positions at Organon Biosciences and at McKinsey.

Nov 19, 2018

Jason Ryan

Jason Ryan will leave his post as CFO of Foundation Medicine to become chief operating and financial officer at Magenta Therapeutics, effective January 1 of 2019. Prior to joining Foundation Medicine, he held management positions for Taligen Therapeutics, Codon Devices, and Genomics Collaborative. Ryan holds a BS in economics from Bates College and an MBA from Babson College. Foundation Medicine has not announced a successor for Ryan yet.

Nov 15, 2018

Roy Smythe

Roy Smythe has been appointed as CEO of SomaLogic. He will replace Alister Reynolds, who became CEO in early 2017 and who will remain on the company's board. Smythe joins the Boulder, Colorado-based firm from Royal Philips, where he was chief medical officer for strategy and partnerships. Prior to that, he was CMO at Valence Health, and before that, CMO of healthcare technology accelerator AVIA. Previously, he was chair of the Department of Surgery at Baylor Scott & White Health and the Texas A&M Health Science Center College of Medicine, where he was also medical director of innovation.

Nov 14, 2018

Glenn Miles

Cancer Genetics has appointed Glenn Miles as its chief financial officer, effective November 26, 2018. In addition, the company said that Igor Gitelman, its current chief accounting officer, will be departing.

Miles has more than 30 years' experience in a variety of accounting and finance roles and has been a full time contractor with Cancer Genetics since this July. Prior to joining Cancer Genetics, he served as President and CFO of management advisory firm Catalytic Consulting, was biopharma controller for Europe, Latin America and US oncology at Pfizer, and held various senior-level finance positions at Lehman Brothers and AT&T Mobility. He holds an MBA from Mercer University and bachelors in commerce and accounting from the University of Alabama.

Nov 13, 2018

Steve Ziganti, Patrik Jeanmonod, Jack Ball, Allen Poirson

Cytek Biosciences announced Steve Ziganti has joined the firm as vice president of worlwide sales and Patrik Jeanmonod has been hired as the company's chief financial officer. 

Additionally, Jack Ball and Allen Poirson have joined Cytek's board of directors. 

Ziganti was previously VP of sales and service at BD Biosciences before retiring from that firm. Jeanmonod has previously held executive positions in finance at Covance, Bridge Pharmaceuticals, and Synteract. He is currently a board member at Seal Biosciences. 

Ball formerly was the CEO of Amnis and CCO of Accuri Cytomers and Molecular Probes. Poirson is a partner at Mighty Capital and previously was CEO of Sony Biotechnology.

Nov 09, 2018

Anne Jones

Anne Jones has been appointed as CEO of Genomics Medicine Ireland. She joins the company from Danaher, where she was vice president and general manager for the Pall Corporations Lab, Food, and Beverage business. Prior to that, she was vice president of strategy and business development at Agilent Technologies. She also held various marketing and R&D roles at Amersham Biosciences in the UK and at GE Healthcare Life Sciences in the UK and the US. Jones holds a undergraduate degree in microbiology and molecular biology from the National University of Ireland and a PhD from Cancer Research UK.

Nov 08, 2018

Jeffrey Jeddeloh, Stephen Macevicz, Christine Peponnet

Jeffrey Jeddeloh, Stephen Macevicz, and Christine Peponnet have joined the new US subsidiary of French DNA synthesis firm DNA Script.  

Jeddeloh was appointed as vice president of business development and commercial strategy. Most recently, he was director of business development for Roche Molecular Solutions. Prior to that, he was R&D director at Orion Genomics. He holds a PhD from Washington University and an MBA from the University of Wisconsin.

Macevicz has become the firm's vice president of intellectual property. Previously, he was vice president of IP at Sequenta and at Ion Torrent, as well as senior IP attorney at Becton Dickinson. He holds a PhD in biophysics and a JD from the University of California, Berkeley.

Peponnet has joined the company as vice president of technology development. Most recently, she was head of the biosystems group at CEA (Center for Atomic Energy), where she helped to develop a microfluidic technology that was licensed to Advanced Liquid Logic, which was later acquired by Illumina. Prior to that, she worked at Caliper Technologies, and before that, she was head of genotyping R&D at Genset.

Nov 08, 2018

Jim Mullen

Jim Mullen has been elected to the board of directors of Thermo Fisher Scientific, bringing the total number of board members to 12. Previously, he was the CEO of Patheon, which Thermo Fisher acquired last year. Prior to that, he was the president and CEO of Biogen Idec. Mullen holds a bachelor of science degree in chemical engineering from Rensselaer Polytechnic Institute and a master's degree in business from Villanova University.

Nov 08, 2018

Scott Tomlins

Strata Oncology has appointed Scott Tomlins as the firm's chief medical officer. Prior to Strata, Tomlins was an associate professor of pathology at the University of Michigan. Tomlins will maintain an adjunct faculty position at the university's medical school. Tomlins' academic research has focused on applying high-throughput techniques to characterize the cancer genome and transcriptome to understand cancer biology and identify clinically relevant biomarkers and therapeutic targets. 

Nov 07, 2018

Scott Nicholson, Cory Dunn

Biocept has appointed Scott Nicholson as its Vice President of Sales in the US and Cory Dunn as its Vice President of Marketing. Nicholson has 24 years of experience in the medical laboratory industry with a focus in oncology for the physician and hospital markets. He has served as a sales manager, executive, district manager, and regional manager in prior positions. Most recently, Nicholson was vice president of sales at GenomeDx, where he led the commercialization effort for the firm's Decipher tests.

Dunn has over 15 years of commercial marketing experience, specializing in diagnostic testing services for oncology. She most recently served as VP of commercial marketing at GenomeDx, where she led the launch, commercial marketing, and product life cycle management of the Decipher suit of tests. Prior to GenomeDx, Dunn oversaw the marketing efforts for Plus Diagnostics' Gastroenterology, Dermatology and Hematology-Oncology product lines. She holds post graduate science and education degrees from the University of California, San Diego and Stanford University, respectively.

In connection with the hirings, Biocept said it granted each individual an inducement stock option award to purchase 24,200 shares of Biocept common stock, with an exercise price per share equal to the closing price of Biocept's common stock on October 31, 2018.

Nov 06, 2018

Marc Stapley

Marc Stapley plans to leave Illumina, effective Jan 1., 2019. Stapley is currently executive vice president of strategy and corporate development at Illumina, where he is responsible for corporate strategy, corporate and business development, and infrastructure. He joined Illumina in 2012 and has held multiple roles with the firm, including as chief financial officer and chief administrative officer. Prior to joining Illumina, he was senior vice president of finance at Pfizer.

Pages

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.